Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense® E3 Starter Kit includes:
- Sensor Kit (Used by the HCP only)
- Pouch with the Sensor inside of a sensor holder
- Smart Transmitter Kit
- Smart Transmitter
- Charging Accessory Pack
- User Guide
- Quick Reference Guide
- Adhesive Patch Kit
- 150 White Adhesives
- 30 Clear Adhesives
Insertion Tool Kit (utilized by the Healthcare Professional performing the insertion)
The Eversense® Charging Accessory Pack includes:
- Charging Cradle (that is used to charge the Smart Transmitter)
- Charging Cable
- Wall Plug
Initialization Phase (after 24-hour Warm-Up Phase)
During the Initialization Phase, four (4) finger stick blood glucose meter tests are required for calibration.
The 4 calibration tests must be spaced 2 to 12 hours apart, and all 4 tests must be completed within a 36 hour period.
– 1st calibration = 24 hours after sensor insertion.
– 2nd calibration = 2 to 12 hours after 1st successful calibration.
– 3rd calibration = 2 to 12 hours after 2nd successful calibration.
– 4th calibration = 2 to 12 hours after 3rd successful calibration.
Glucose readings will start displaying in the app a few minutes after the 2nd calibration is successfully completed.
The system will re-enter Initialization Phase for any one of the following reasons:
- Calibration period has expired without you having entered a fingerstick test value.
- 3 or more blood glucose readings are significantly different than the current sensor glucose readings.
- Y our smart transmitter has not been charged within 16 hours of the empty battery alert.
- If you manually change the time on your mobile device your smart transmitter will sync and reinitialize to your mobile device.
- A new transmitter has been linked to your existing sensor. For example, if you have replaced your existing transmitter.
- If you were instructed by Customer Support to re-link your sensor.
The Eversense® E3 CGM System measures glucose in interstitial fluid (ISF) between the body’s cells.Physiologic differences between ISF and blood from a finger stick may result in differences in glucose measurements. These differences are especially evident during times of rapid change in blood glucose (e.g., after eating, dosing insulin, or exercising). On average, glucose levels in ISF lag behind glucose levels in blood by several minutes.
The trend arrow on the My Glucose screen of the Eversense® App screen will give you an indication of which direction the glucose is moving towards, up or down and the rate of change.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060